Centogene launches new centogenome®, world's most comprehensive whole genome sequencing solution for diagnosis of rare and neurodegenerative diseases

Cambridge, mass. and rostock, germany and berlin, april 12, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of new centogenome®, an enhanced next generation sequencing (ngs)-based assay. healthcare professionals can leverage new centogenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.
CNTG Ratings Summary
CNTG Quant Ranking